Sanofi's Lovenox Authorized Generic Could Help Speed Amphastar's Path To Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Availability of an authorized generic since mid-October could make it more difficult for commercial partners Momenta and Sandoz to prove they are likely to suffer irreparable harm unless Amphastar and Watson are enjoined from marketing their generic of the low molecular weight heparin.
You may also be interested in...
Generic Lovenox Battle Heats Up With Amphastar’s ANDA Approval
Momenta Pharmaceuticals and Sandoz have enjoyed approximately 14 months of de facto generic exclusivity on Sanofi’s anticoagulant Lovenox (enoxaparin), but faced with the imminent threat of competition they are trying to maintain their hold on the market through patent litigation.
FDA Approves Momenta/Sandoz' Lovenox Generic Without Need For Clinical Studies
Agency's five criteria for determining "sameness" of generic enoxaparin to Sanofi-Aventis's low molecular weight heparin could serve as guideposts for future biosimilar approvals.